Anti-MYD88 Antibody (R2J93)

Catalog No.

RHJ47401

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

FCM: 1:20-1:100, IF: 1:50-1:200, IHC: 1:100-1:200, WB: 1:1000-1:2000

Target

MYD88, Myeloid differentiation primary response protein MyD88

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q99836

Applications

FCM, IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2J93

Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study., PMID:40475774

Cardio-Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity., PMID:40427493

Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198

[Application of next-generation sequencing technology for the investigation of immunoglobulin variable region characteristics and their prognostic significance in patients with chronic lymphocytic leukemia]., PMID:40355356

Dynamics of antimicrobial proteins' expression and their bactericidal activity in mouse milk., PMID:40345232

Early Recognition of Retinal Signs in Waldenström's Macroglobulinemia: Implications for Therapeutic Plasma Exchange., PMID:40329702

Discovery of novel adjuvants: Identification of saponins from Hylomecon japonica (Thunb.) Prantl & Kündig and insights into their in vitro and in vivo activities., PMID:40318505

Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation., PMID:40304491

LPS-induced extracellular AREG triggers macrophage pyroptosis through the EGFR/TLR4 signaling pathway., PMID:40292295

Ginsenosides modulate immunity via TLR4/MyD88/NF-κB pathway and gut microbiota., PMID:40252438

Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory., PMID:40205909

Extraction technology, component analysis, and the immunomodulatory effects in immunosuppressed broilers of total flavonoids extract from the thorns of Gleditsia sinensis Lam., PMID:40204053

[Relapse-related candidate genes and their clinicopathological connections of diffuse large B cell lymphoma]., PMID:40159024

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review., PMID:40127387

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management., PMID:40095219

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy., PMID:40084099

PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling., PMID:40076547

A genome wide CRISPR screen reveals novel determinants of long-lived plasma cell secretory capacity., PMID:40060628

Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control., PMID:40060445

DNA Receptor Toll-Like Receptor 9 Signaling Pathway Plays a Major Immunomodulatory Role in Neonatal Acute Lung Injury by Inhibiting Inflammatory Response and Oxidative Stress., PMID:40053211

SARS-CoV-2 infection primes cross-protective respiratory IgA in a MyD88- and MAVS-dependent manner., PMID:40016252

A case of renal infiltration by Bence Jones protein kappa-producing lymphoplasmacytic lymphoma., PMID:39946076

Impaired LPS Signaling in Macrophages Overexpressing the P2X7 C-Terminal Domain or Anti-P2X7 C-Terminal Domain Intrabody., PMID:39940947

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome., PMID:39935483

Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia., PMID:39929803

Pseudomonas aeruginosa infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection., PMID:39908350

Extracellular vesicle surface engineering with integrins (ITGAL & ITGB2) to specifically target ICAM-1-expressing endothelial cells., PMID:39885580

Hans's algorithm and MYD88L265P mutation may affect prognosis of primary central nervous system B-cell lymphoma., PMID:39880607

An attenuated live strain of HY9901 mutant Δgr provides protection against Vibrio alginolyticus in pearl gentian grouper (♀Epinephelus fuscoguttatus × ♂Epinephelus lanceolatu)., PMID:39874646

CD20 and CD19 promote proliferation driven by the IgM-TLR9-L265P MyD88 complex., PMID:39868594

Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome., PMID:39859314

Enhanced Immunogenicity of Foot-and-Mouth Disease Virus-like Particles Using a Water-in-Oil-in-Water Adjuvant., PMID:39852803

Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study., PMID:39748728

[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma]., PMID:39743255

Immunostimulatory effects of Heyndrickxia coagulans SANK70258., PMID:39732622

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)., PMID:39711167

TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma., PMID:39691999

Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation., PMID:39660959

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia., PMID:39626287

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial., PMID:39604169

IgG autoantibodies in bullous pemphigoid directly induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes., PMID:39569141

Threonine attenuates lipopolysaccharide-induced intestinal inflammatory responses in rabbits., PMID:39549129

High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma : Identification of an MCD-like Subtype., PMID:39483112

Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer., PMID:39459842

T lymphocyte-dependent IL-10 down-regulates a cytokine storm driven by Toxoplasma gondii GRA24., PMID:39440975

Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma., PMID:39428323

[Efficacy and safety analysis of the OR-CHOP regimen for the treatment of MCD subtype diffuse large B cell lymphoma in the real-world setting]., PMID:39414605

Tumour cell-released autophagosomes promote lung metastasis by upregulating PD-L1 expression in pulmonary vascular endothelial cells in breast cancer., PMID:39373859

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:39358470

Paraneoplastic myelitis associated with Waldenström macroglobulinemia responsive to treatment with ibrutinib - venetoclax: A case report., PMID:39309451

Document Download

Anti-MYD88 Antibody (R2J93).pdf